Spots Global Cancer Trial Database for Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Official Title: A Prospective, Single-arm Clinical Trial of Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Study ID: NCT05237349
Study Description
Brief Summary: The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma.
Detailed Description: Envafolimab indication: Envafolimab is the world's first subcutaneous injection of PD-L1 monoclonal antibody.Suitable for adult patients with advanced solid tumors with unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair gene defects (dMMR).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Contact Details
Name: Liangjun Zhu
Affiliation: Jiangsu Cancer Institute & Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
